Ramucirumab: First global approval

Drugs

Volumn 74, Issue 9, 2014, Pages 1047-1058

  Poole, Raewyn M ^b   Vaidya, Asha ^a  

^a Adis Level 1 ^*  (New Zealand)

^b ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROPYRIMIDINE; PLATINUM; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN; VASCULOTROPIN RECEPTOR 2;

ADVANCED CANCER; ANEMIA; ARTICLE; BREAST CANCER; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG APPROVAL; DRUG INDICATION; FISTULA; HUMAN; HYPERTENSION; IMMUNOGENICITY; INFUSION RELATED REACTION; INTESTINE OBSTRUCTION; KIDNEY CANCER; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; MONOTHERAPY; OVARY CANCER; PHARMACODYNAMICS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROSTATE CANCER; PROTEINURIA; STOMACH CANCER; THROMBOEMBOLISM; UNITED STATES; WOUND HEALING IMPAIRMENT; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; ESOPHAGEAL NEOPLASMS; LOWER ESOPHAGUS SPHINCTER; PATHOLOGY; STOMACH NEOPLASMS;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DRUG APPROVAL; DRUG SCREENING ASSAYS, ANTITUMOR; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84904044814     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0244-2     Document Type: Article

References (53)

1. Krupitskaya Y, Wakelee HA. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs. 2009;10(6):597-605.
2. Qiu M-Z, Xu R-H. The progress of targeted therapy in advanced gastric cancer. Biomark Res. 2013;1(1):32.
3. Frenette C, Gish R. Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications. World J Gastroenterol. 2012;18(6):498-506.
4. Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs. 2009;23(5):289-304.
5. Aprile G, Bonotto M, Ongaro E, et al. Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use. Drugs. 2013;73(18):2003-15.
6. Meza-Junco J, Sawyer MB. Metastatic gastric cancer - focus on targeted therapies. Biologics. 2012;6:137-46.
7. Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273(2):114-27.
8. Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996;77(5):858-63.
9. Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012;30(17):2119-27.
10. Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther. 2013;13(8):1187-96.
11. US Food and Drug Administration. Ramucirumab. 2014. http://www.fdagov/ drugs/informationondrugs/approveddrugs/ucm394260htm.
12. Eli Lilly and Company. Ramucirumab: Prescribing information. 2014. http://www.accessdatafdagov/drugsatfda-docs/label/2014/125477lblpdf.
13. Eli Lilly and Company. Lilly details progress on achieving strategic business goals and its advancing pipeline to investment community. Media Release. 2013.
14. European Commission. Community register of orphan medicinal products: Ramucirumab for the treatment of hepatocellular carcinoma. 2012. http://ec.europa.eu/health/documents/community-register/html/o1019.htm. Accessed.
15. European Commission. Community register of orphan medicinal products: Ramucirumab for the treatment of gastric cancer. 2012. http://ec.europa.eu/ health/documents/community-register/html/o1004.htm. Accessed.
16. US Food and Drug Administration. Orphan drug designations: ramucirumab for hepatocellular carcinoma. 2011. http://www.accessdata.fda.gov/scripts/ opdlisting/oopd/OOPD-Results-2.cfm?Index-Number=353911. Accessed.
17. US Food and Drug Administration. Orphan drug designations and approvals: ramucirumab for gastric cancer. 2012. http://www.accessdata.fda.gov/scripts/ opdlisting/oopd/OOPD-Results-2.cfm?Index-Number=359711. Accessed.
18. Eli Lilly and Company. Lilly announces second positive ramucirumab phase III gastric cancer study meets primary endpoint; phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint Media Release. 2013.
19. Eli Lilly and Company. Lilly completes acquisition of ImClone systems. Media Release. 2008.
20. Biologics Inc. Biologics, Inc. to be Exclusive Specialty Pharmacy Provider of Eli Lilly's CYRAMZA™ (ramucirumab).
21. Dyax Corp. Dyax enters into antibody library license agreement with ImClone systems incorporated. Media Release. 2003.
22. Dyax Corp. Dyax announces developments in licensing and funded research program. Media Release. 2009.
23. Franklin MC, Navarro EC, Wang Y, et al. The structural basis for the function of two anti-VEGF receptor 2 antibodies. Structure. 2011;19(8):1097-107.
24. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010;28(5):780-7.
25. Zhu AX, Finn RS, Mulcahy M, et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res. 2013;19(23):6614-23.
26. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31-9.
27. Wilke H, Van Cutsem E, Oh SC, et al. RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE). J Clin Oncol Conf. 2014;32(3 Suppl):abstr. LBA7.
28. Mackey JR, Ramos-Vazquez M, Lipatov O, et al. Primary results of ROSE/TRIO-12, a randomized placebo controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. 36th Annual San Antonio Breast Cancer Symposium. 2013:abstr. S5-04.
29. Garcia-Carbonero R, Rivera F, Maurel J, et al. An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. Oncologist. 2014;19(4):350-1.
30. Garcia-Carbonero R, Rivera F, Maurel J, et al. A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): CP12-0709/NCT00862784. J Clin Oncol Conf. 2012;30(4 Suppl):abstr. 533.
31. Yoshino T, Yamazaki K, Yoshida M, et al. A phase (Ph) Ib study of irinotecan (IRI), levofolinate (LV), and 5-fluorouracil (5-FU) (FOLFIRI) plus ramucirumab (RAM; IMC-1121B) drug product in Japanese (JP) patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (CP12-1029/NCT01286818). J Clin Oncol Conf. 2013;31(4 Suppl):abstr. 591.
32. Doebele RC, Spigel D, Tehfe M, et al. A phase 2 randomized open-label study of ramucirumab (IMC 1121B; RAM) in combination with first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): Final results from non-squamous (NSQ) pts (NCT01160744). J Thorac Oncol. 2013;8:S290.
33. Camidge DR, Ballas MS, Dubey S, et al. A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC). J Clin Oncol Conf. 2010;28(15 Suppl 1):abstr. 7588.
34. Carvajal R, Thompson J, Gordon M, et al. A Phase 2 Randomized Study of Ramucirumab (Imc 1121B; Ram) with or Without Dacarbazine (Dtic) in Patients (Pts) with Metastatic Melanoma (Mm) (Cp12-0604/Nct00533702). 37th Congress of the European Society for Medical Oncology. 2012:abstr. 1115PD.
35. Penson RT, Moore KN, Fleming GF, et al. A phase II, open-label, multicenter study of IMC-1121B (ramucirumab; RAM) monotherapy in the treatment of persistent or recurrent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal (PPC) carcinoma (CP12-0711/NCT00721162). J Clin Oncol Conf. 2012;30(15 Suppl):abstr. 5012.
36. Hussain M, Rathkopf DE, Liu G, et al. A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy. J Clin Oncol Conf. 2012;30(5 Suppl 1): abstr. 97
37. Garcia JA, Hudes GR, Choueiri TK, et al. Phase II study of IMC-1121B in patients with metastatic renal cancer (mRCC) following VEGFR-2 tyrosine kinase inhibitor (TKI) therapy (IMCL CP12-0605/ NCT00515697). Genitourin Cancers Symp. 2010:abstr. 326.
38. Eli Lilly and Company. A study of paclitaxel with or without ramucirumab in metastatic gastric adenocarcinoma (RAINBOW) [ClinicalTrials.gov identifier NCT01170663]. US National Institutes of Health, ClinicalTrialsgov 2010.
39. Eli Lilly and Company. Phase III study of docetaxel + ramucirumab or placebo in breast cancer [ClinicalTrials.gov identifier NCT00703326]. US National Institutes of Health, ClinicalTrialsgov. 2008.
40. Eli Lilly and Company. A study in second line metastatic colorectal cancer [ClinicalTrials.gov identifier NCT01183780]. US National Institutes of Health, ClinicalTrialsgov. 2010.
41. Eli Lilly and Company. A study of ramucirumab (IMC-1121B) drug product (DP) and best supportive care (BSC) versus placebo and BSC as 2nd-line treatment in patients with hepatocellular carcinoma after 1st-line therapy with sorafenib (REACH) [ClinicalTrials.gov identifier NCT01140347]. US National Institutes of Health, ClinicalTrialsgov. 2010.
42. Eli Lilly and Company. A study of chemotherapy and ramucirumab vs. chemotherapy alone in second line non-small cell lung cancer participants who received prior first line platinum based chemotherapy [ClinicalTrials.gov identifier NCT01168973]. US National Institutes of Health, ClinicalTrialsgov. 2010.
43. Eli Lilly and Company. Study of ramucirumab or IMC-18F1 with docetaxel or docetaxel alone as second-line therapy in participants with bladder, urethra, ureter, or renal pelvis carcinoma [ClinicalTrials.gov identifier NCT01282463]. US National Institutes of Health, ClinicalTrialsgov. 2011.
44. Eli Lilly and Company. A study of ramucirumab in treating japanese participants with metastatic gastric or gastroesophageal junction cancer [ClinicalTrials.gov identifier NCT01983878]. US National Institutes of Health, ClinicalTrialsgov. 2013.
45. Eli Lilly and Company. A study of ramucirumab in patients with gastric, esophageal and gastroesophageal cancer [ClinicalTrials.gov identifier NCT01246960]. US National Institutes of Health, ClinicalTrialsgov. 2010.
46. Eli Lilly and Company. a study of ramucirumab (IMC-1121B) in combination with eribulin versus eribulin alone in patients with breast cancer [ClinicalTrials.gov identifier NCT01427933]. US National Institutes of Health, ClinicalTrialsgov. 2011.
47. Eli Lilly and Company. Study of IMC-18F1 or ramucirumab DP in combination with capecitabine or capecitabine on previously treated breast cancer patients [ClinicalTrials.gov identifier NCT01234402]. US National Institutes of Health, ClinicalTrialsgov. 2010.
48. Eli Lilly and Company. A study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV Non-small cell lung cancer [ClinicalTrials.gov identifier NCT01703091]. US National Institutes of Health, ClinicalTrialsgov. 2012.
49. Eli Lilly and Company. A study of pemetrexed & carboplatin/cisplatin or gemcitabine & carboplatin/cisplatin with or without IMC-1121B in patients previously untreated with recurrent or advanced non-small cell lung cancer (NSCLC) [ClinicalTrials.gov identifier NCT01160744]. US National Institutes of Health, ClinicalTrialsgov. 2010.
50. Eli Lilly and Company. Study of ramucirumab in ovarian cancer [ClinicalTrials.gov identifier NCT00721162]. US National Institutes of Health, ClinicalTrialsgov. 2008.
51. Eli Lilly and Company. A study to assess the pharmacokinetics of ramucirumab in combination with FOLFIRI [ClinicalTrials.gov identifier NCT01634555]. US National Institutes of Health, ClinicalTrialsgov. 2012.
52. Eli Lilly and Company. A study of ramucirumab (IMC-1121B) and paclitaxel in participants with solid tumors [ClinicalTrials.gov identifier NCT01515306]. US National Institutes of Health, ClinicalTrialsgov. 2012.
53. Eli Lilly and Company. Study of ramucirumab (IMC-1121B) therapy and corrected QT (QTc) interval changes [ClinicalTrials.gov identifier NCT01017731]. US National Institutes of Health, ClinicalTrialsgov. 2009.